Mechanisms of Drugs-resistance in Small Cell Lung Cancer: DNA-related, RNA-related, Apoptosis-related, Drug Accumulation and Metabolism Procedure

Overview

Journal Transl Lung Cancer Res

Date 2020 Jul 18

PMID 32676338

Citations 17

Authors

Peixin Chen

Peng Kuang

Lei Wang

Wei Li

Bin Chen

Yu Liu

Hao Wang

Sha Zhao

Lingyun Ye

Feng Yu

Yayi He

Caicun Zhou

Affiliations

Soon will be listed here.

Abstract

Small-cell lung cancer (SCLC), the highest malignant cancer amongst different types of lung cancer, has the feature of lower differentiation, rapid growth, and poor survival rate. Despite the dramatically initial sensitivity of SCLC to various types of treatment methods, including chemotherapy, radiotherapy and immunotherapy, the emergence of drugs-resistance is still a grandly clinical challenge. Therefore, in order to improve the prognosis and develop new therapeutic approaches, having a better understanding of the complex mechanisms of resistance in SCLC is of great clinical significance. This review summarized recent advances in understanding of multiple mechanisms which are involved in the resistance during SCLC treatment, including DNA-related process, RNA-related process, apoptosis-related mechanism, and the process of drug accumulation and metabolism.

Citing Articles

Etoposide as a Key Therapeutic Agent in Lung Cancer: Mechanisms, Efficacy, and Emerging Strategies.

Jang J, Kim D, Im E, Kim N Int J Mol Sci. 2025; 26(2).

PMID: 39859509 PMC: 11765581. DOI: 10.3390/ijms26020796.

Bioprocessing of Epothilone B from Aspergillus fumigatus under solid state fermentation: Antiproliferative activity, tubulin polymerization and cell cycle analysis.

El-Sayed A, Shindia A, Ammar H, Seadawy M, Khashana S BMC Microbiol. 2024; 24(1):43.

PMID: 38291363 PMC: 10829302. DOI: 10.1186/s12866-024-03184-w.

CD209 signaling pathway as a biomarker for cisplatin chemotherapy response in small cell lung cancer.

Lin A, Yang H, Zhang J, Luo P Genes Dis. 2024; 11(3):101038.

PMID: 38274378 PMC: 10806268. DOI: 10.1016/j.gendis.2023.06.011.

Simplified Synthesis of Renieramycin T Derivatives to Target Cancer Stem Cells via β-Catenin Proteasomal Degradation in Human Lung Cancer.

Ei Z, Racha S, Yokoya M, Hotta D, Zou H, Chanvorachote P Mar Drugs. 2023; 21(12).

PMID: 38132948 PMC: 10744608. DOI: 10.3390/md21120627.

ING5 overexpression upregulates miR-34c-5p/Snail1 to inhibit EMT and invasion of lung cancer cells.

Yang J, Liu X, Sun Y, Zhang X, Zhao Y, Zhang H Acta Biochim Biophys Sin (Shanghai). 2023; 55(5):809-817.

PMID: 37249332 PMC: 10281876. DOI: 10.3724/abbs.2023074.

References

Caffrey P, Frenkel G, McAndrew K, Marks K . A Model of the Development of Cisplatin Resistance in Human Small Cell Lung Cancer Xenografts. In Vivo. 2016; 30(6):745-749. DOI: 10.21873/invivo.10990. View

Ma W, Ma C, Li X, Zhang Y . Examining the effect of gene reduction in miR-95 and enhanced radiosensitivity in non-small cell lung cancer. Cancer Gene Ther. 2016; 23(2-3):66-71. DOI: 10.1038/cgt.2016.2. View

Chen F, Arseven O, Cryns V . Proteolysis of the mismatch repair protein MLH1 by caspase-3 promotes DNA damage-induced apoptosis. J Biol Chem. 2004; 279(26):27542-8. DOI: 10.1074/jbc.M400971200. View

Tran N, McDonough W, Donohue P, Winkles J, Berens T, Ross K . The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol. 2003; 162(4):1313-21. PMC: 1851233. DOI: 10.1016/S0002-9440(10)63927-2. View

Siddik Z . Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22(47):7265-79. DOI: 10.1038/sj.onc.1206933. View

Takano M, Sugiyama T . UGT1A1 polymorphisms in cancer: impact on irinotecan treatment. Pharmgenomics Pers Med. 2017; 10:61-68. PMC: 5338934. DOI: 10.2147/PGPM.S108656. View

Kim E . Chemotherapy Resistance in Lung Cancer. Adv Exp Med Biol. 2015; 893:189-209. DOI: 10.1007/978-3-319-24223-1_10. View

Antonia S, Lopez-Martin J, Bendell J, Ott P, Taylor M, Eder J . Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016; 17(7):883-895. DOI: 10.1016/S1470-2045(16)30098-5. View

Leonetti A, Facchinetti F, Minari R, Cortellini A, Rolfo C, Giovannetti E . Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges. Cell Oncol (Dordr). 2019; 42(3):261-273. DOI: 10.1007/s13402-019-00441-3. View

10.

Liu H, Huang J, Peng J, Wu X, Zhang Y, Zhu W . Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway. Mol Cancer. 2015; 14:59. PMC: 4373128. DOI: 10.1186/s12943-015-0298-0. View

11.

Kelland L . New platinum antitumor complexes. Crit Rev Oncol Hematol. 1993; 15(3):191-219. DOI: 10.1016/1040-8428(93)90042-3. View

12.

Owonikoko T, Dahlberg S, Sica G, Wagner L, Wade 3rd J, Srkalovic G . Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. J Clin Oncol. 2018; 37(3):222-229. PMC: 6338394. DOI: 10.1200/JCO.18.00264. View

13.

Vilborg A, Glahder J, Wilhelm M, Bersani C, Corcoran M, Mahmoudi S . The p53 target Wig-1 regulates p53 mRNA stability through an AU-rich element. Proc Natl Acad Sci U S A. 2009; 106(37):15756-61. PMC: 2773521. DOI: 10.1073/pnas.0900862106. View

14.

Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J . miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol. 2011; 69(3):723-31. DOI: 10.1007/s00280-011-1752-3. View

15.

Ott P, Elez E, Hiret S, Kim D, Morosky A, Saraf S . Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. J Clin Oncol. 2017; 35(34):3823-3829. DOI: 10.1200/JCO.2017.72.5069. View

16.

KERR J, Winterford C, Harmon B . Apoptosis. Its significance in cancer and cancer therapy. Cancer. 1994; 73(8):2013-26. DOI: 10.1002/1097-0142(19940415)73:8<2013::aid-cncr2820730802>3.0.co;2-j. View

17.

Kalemkerian G, Akerley W, Bogner P, Borghaei H, Chow L, Downey R . Small cell lung cancer. J Natl Compr Canc Netw. 2013; 11(1):78-98. PMC: 3715060. DOI: 10.6004/jnccn.2013.0011. View

18.

Perego P, Giarola M, Righetti S, Supino R, Caserini C, Delia D . Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res. 1996; 56(3):556-62. View

19.

Sakamoto M, Kondo A, Kawasaki K, Goto T, Sakamoto H, Miyake K . Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum Cell. 2002; 14(4):305-15. View

20.

Haslehurst A, Koti M, Dharsee M, Nuin P, Evans K, Geraci J . EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer. 2012; 12:91. PMC: 3342883. DOI: 10.1186/1471-2407-12-91. View